drugset / Trial / NCT01406418
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
Phase 1
Completed
64 enrolled
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal antibody against influenza A viruses.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DIRIDAVUMAB | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | DIRIDAVUMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | DIRIDAVUMAB | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | DIRIDAVUMAB | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | DIRIDAVUMAB | Monoclonal antibody | 50 mg/kg | Intravenous |